Pharma Sector

Pharmarack data show anti-bacterial unit sales falling since 2023; experts say lower volumes alone do not indicate more appropriate antibiotic use

Natco Pharma on Tuesday said it is investing USD 14 million (over Rs 130 crore) in eGenesis Inc, a US-based biotechnology firm, through its two subsidiaries. As part of the transaction, Natco Pharma (Canada) Inc will invest USD 9.5 million and Natco Pharma South Africa Proprietary Ltd USD 4.5 million in eGenesis through convertible promissory notes, the Hyderabad-based company said in a regulatory filing. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure, it added. In 2024, Natco Pharma had invested USD 8 million in eGenesis, Inc through preferred stock. The total investment made by it in eGenesis, Inc now stands at USD 22 million, the company said. The eGenesis Genome Engineering and Production (EGEN) platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via ..

Trump's pledge to apply 100% levy on firms making off-patent medications by 2028 (rising to 200% a year later) unless they move production to US faces formidable commercial and political obstacles

The product has been launched in 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, along with a 10,000 mg/100 mL pharmacy bulk package

Govt's decision under the ₹10,000 cr Biopharma SHAKTI programme to create a dedicated scientific review cadre within CDSCO is an important reform

The successful closure of the inspection further strengthens Strides' regulatory track record and reinforces the company's commitment to supplying high-quality pharma products to patients across globe

India's pharmaceutical industry needs to move beyond its traditional strength in cost-effective generic medicines and focus on innovation, advanced manufacturing, quality and global regulatory standards to realise its growth potential, industry experts said. With India targeting a pharmaceutical market of USD 130 billion by 2030, experts at a recent industry event in Hyderabad said the next phase of growth would require greater investments in research and development, digital technologies and contract research and development manufacturing. The discussions were held ahead of the 19th edition of CPHI & PMEC India 2026, scheduled to be held in November across venues in Delhi-NCR. The official launch and precursor event of CPHI & PMEC India 2026, held under the banner of the Pharma Leadership Exchange, brought together pharma leaders, CXOs, industry stalwarts, and key voices from across India's pharmaceutical and life sciences ecosystem. Sarvesh Singh, CEO, Lifesciences and ...

The policy covers pharmaceutical products, bulk drugs, active pharmaceutical ingredients, key starting materials, drug intermediates, medical devices and related manufacturing infrastructure

The company is evaluating specialised CROs, data-management and patient-recruitment businesses as it looks to expand across the pharmaceutical value chain

The US-based company said it is eyeing continued double-digit growth in India driven by rising demand from biopharma, semiconductor, and clean energy sectors

Homegrown pharma major Lupin Ltd has reported a 16 per cent rise in consolidated profit after tax at Rs 1,416.98 crore in the first quarter ended June 30, riding on robust growth across its key markets. The company had posted a consolidated Profit After Tax (PAT) at Rs 1,221.46 crore in the corresponding period last fiscal, Lupin Ltd said in a regulatory filing on Thursday. Consolidated total revenue from operations in the first quarter was at Rs 8,276.89 crore as against Rs 6,268.34 crore in the year-ago period, it added. Total expenses in the quarter under review rose at Rs 6,389.83 crore as compared to Rs 4,931.84 crore in the corresponding period last fiscal, the company said. Commenting on the performance, Lupin Ltd Managing Director Nilesh Gupta said, "We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability." The company's focus on execution, operational excellence, and sustained ...

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

A potential deal would carry regulatory risk because of concerns about how it might be assessed by US antitrust authorities under ‌President Donald Trump's administration

Industry seeks AI-based submission tools and unified digital portals to accelerate approvals and compliance tracking

Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

Dahej facility to begin commercial production in FY28; company targets nutraceuticals, functional foods and import substitution

Share price of Rubicon Research hit a new high of ₹1,545.60, rallying 6 per cent on the BSE in Thursday's intra-day deals in an otherwise weak market.

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period